In court decision to approve generic colchicine for gout, American College of Rheumatology arguments about the risk to patients of exorbitant pricing may have played an important role. Is this a harbinger of something?
(VIDEO) A gout drug with a new mechanism is showing promise in combination with existing remedies. In this interview, a leader in its progress to market tells why lesinurad could help put an undertreated disorder in a new light.
(ACR2014) Our rheumatologist correspondent found three issues of particular interest: a biomarker test that has gone quickly to market, new diagnostic criteria for gout, and the potential of ultrasound for Sjögren syndrome.
(ACR2014) These researchers learned what is actually happening to many gout patients who flare, and offer powerful reasons for its doctors to do better.
Treating gout with allopurinol is certainly less costly than no treatment whatever, all things considered. But a study shows even a more expensive combination may be cost-effective too.
A large population-based study, the first on the question to include women, stratifies an increased risk for type 2 diabetes among gout patients.
The 45-year-old woman turned up in the emergency room with an acutely painful, swollen thumb. Aspiration results were uninformative. What's the diagnosis?
(VIDEO) The fourth "Sounding Out Arthritis" video demonstrates how to use ultrasound to distinguish gout from pseudogout, with a demonstration of probe placement and narrated ultrasound images and videos.
Unpublished results from Phase III trials of the uric acid inhibitor lesinurad offer promise of help for gout patients who have not reached treatment targets with allopurinol or febuxostat.
A month after being diagnosed with gout, this woman returned for care with pain, swelling, and effusion in both knees. Can you guess the diagnosis?